ArticleAmerican journal of translational research2025
Knockdown of TIM1 enhances platinum chemosensitivity and inhibits progression through the MAPK signaling pathway in gastric cancer.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe incidence of gastric cancer (GC) is increasing worldwide, and it ranks among the leading causes of cancer-related mortality. Platinum-based chemotherapeutic agents are commonly employed in the treatment of various solid tumors; however, the development of drug resistance remains a crucial barrier to effective treatment. T cell immunoglobulin and mucin domain 1 (TIM1) has been implicated in the initiation and progression of various tumors. Nevertheless, the influence of TIM1 on the efficacy of platinum-based chemotherapeutics and its biologic implications in GC have not been thoroughly investigated.
methodsThis study utilized flow cytometry, cell counting kit-8 assays, and western blot to assess the role of TIM1 in modulating sensitivity to platinum drugs. High-throughput sequencing was employed to elucidate the potential mechanism of TIM1. Additionally, the effect of TIM1 on the biologic characteristics of GC was further investigated through clinical specimens, cells, and animals.
resultsKnockdown of TIM1 enhanced the sensitivity of GC cells to platinum chemotherapeutic drugs. Furthermore, TIM1 expression was elevated in GC tissues, and high TIM1 expression predicted poor survival outcomes in GC patients. Knockdown of TIM1 inhibited the malignant behaviors of GC cells in vitro and in vivo. The mitogen-activated protein kinase (MAPK) signaling pathway may play a role in the regulatory effects of TIM1 on GC cells.
conclusionsOverall, TIM1 functions as an oncogene in GC. Knockdown of TIM1 enhances platinum chemosensitivity and inhibits malignant behavior in GC through the MAPK signaling pathway. These findings reveal a molecular mechanism contributing to chemotherapy resistance and suggest a therapeutic strategy for enhancing chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.